J. Juengsamarn, E. Sirachainan, T. Reungwetwattana
{"title":"停用克唑替尼后alk阳性非小细胞肺癌脑转移的快速爆发","authors":"J. Juengsamarn, E. Sirachainan, T. Reungwetwattana","doi":"10.21767/2254-6081.1000146","DOIUrl":null,"url":null,"abstract":"The prevalence of Anaplastic lymphoma kinase(ALK) rearrangement in NSCLC is about 7-10%. Currently, there are several ALK inhibitors available in treating this group of patients. Brain metastases occur in approximately 30% of patients with ALK-positive non-small-cell lung cancer (NSCLC), and in patients treated with ALK inhibitor, CNS progression occurs in up to 70% of patients. Patients with brain metastases from ALK-positive NSCLC have a distinct natural history compared with patients with wild-type NSCLC. This article describes the rapid flare of brain metastases in ALK-positive non-small cell lung cancer after stopping Crizotinib.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.1000146","citationCount":"0","resultStr":"{\"title\":\"Rapid Flare of Brain Metastases in ALK-Positive Non-Small Cell Lung Cancer after Stopping Crizotinib\",\"authors\":\"J. Juengsamarn, E. Sirachainan, T. Reungwetwattana\",\"doi\":\"10.21767/2254-6081.1000146\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The prevalence of Anaplastic lymphoma kinase(ALK) rearrangement in NSCLC is about 7-10%. Currently, there are several ALK inhibitors available in treating this group of patients. Brain metastases occur in approximately 30% of patients with ALK-positive non-small-cell lung cancer (NSCLC), and in patients treated with ALK inhibitor, CNS progression occurs in up to 70% of patients. Patients with brain metastases from ALK-positive NSCLC have a distinct natural history compared with patients with wild-type NSCLC. This article describes the rapid flare of brain metastases in ALK-positive non-small cell lung cancer after stopping Crizotinib.\",\"PeriodicalId\":91204,\"journal\":{\"name\":\"Archives in cancer research\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.21767/2254-6081.1000146\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives in cancer research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21767/2254-6081.1000146\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives in cancer research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21767/2254-6081.1000146","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Rapid Flare of Brain Metastases in ALK-Positive Non-Small Cell Lung Cancer after Stopping Crizotinib
The prevalence of Anaplastic lymphoma kinase(ALK) rearrangement in NSCLC is about 7-10%. Currently, there are several ALK inhibitors available in treating this group of patients. Brain metastases occur in approximately 30% of patients with ALK-positive non-small-cell lung cancer (NSCLC), and in patients treated with ALK inhibitor, CNS progression occurs in up to 70% of patients. Patients with brain metastases from ALK-positive NSCLC have a distinct natural history compared with patients with wild-type NSCLC. This article describes the rapid flare of brain metastases in ALK-positive non-small cell lung cancer after stopping Crizotinib.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
